Regulatory roundup: BioMarin poised to have first U.S., EU hemophilia gene therapy; plus Allergan, Eisai, FibroGen, ViiV and Vero

Monday's basket of regulatory news includes two landmark regulatory applications for BioMarin's hemophilia gene therapy in the U.S. and EU, and FDA approval of Allergan's migraine drug.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) submitted a BLA to FDA for valoctocogene roxaparvovec for hemophilia A and announced EMA accepted an MAA for the adeno-associated virus subtype 5 (AAV5) vector delivering Factor VIII to treat severe hemophilia A...